CRISPR Therapeutics CEO’s Stock Sales Trigger Market Reaction
CRISPR Therapeutics AG (CRSP) shares fell 5.8% this week following CEO Samarth Kulkarni's sale of $5.17 million in company stock. The transactions, executed at $51.75 and $60.23 per share respectively, reduced Kulkarni's direct holdings by 40%.
Bank of America maintained its bullish outlook despite trimming its price target to $89, citing tempered expectations for Casgevy's 2026 performance. The analyst consensus remains neutral with a $68.15 average target, reflecting the biotech sector's characteristic volatility.